IngredientesSaccharomyces boulardii is a yeast first isolated in 1923 from lychee (Litchi chinensis) and mangosteen (Garcinia mangostana) fruit peels by the French scientist Henri Boulard. Early reports described S. boulardii as a distinct species with unique taxonomic, metabolic, and genetic characteristics; however, subsequent genomic analyses have shown that it is not a separate species but a lineage of Saccharomyces cerevisiae, sharing greater than 99% genomic sequence identity with other S. cerevisiae strains. As a result, it is often referred to as S. cerevisiae var. boulardii.
Sequences of the D1/D2 domain of the 26S rDNA were identical for all strains examined and had a similarity value of 100% compared to sequences of the type strain of S. cerevisiae (CBS 1171T) and strain S288c. For all S. boulardii isolates the exact same ITS1-5.8S rDNA-ITS2 sequence was found, which displayed a close resemblance with the sequences published for S288c (99.9%). Sequence analysis of the mitochondrial cytochrome-c oxidase II gene (COX2) also resulted in identical sequences for the S. boulardii isolates and comparisons revealed close relatedness to strains of S. cerevisiae including S288c (99.5%) and CBS 1171T (96.6%).
Despite this genomic closeness, S. boulardii retains several distinctive phenotypic traits relevant to its use as a probiotic. Unlike typical baker's or brewer's yeast, S. boulardii thrives at human body temperature (37°C) and demonstrates resilience to gastric acidity (pH 2), enabling it to reach the intestines alive where it temporarily colonizes the gut without permanent residency.
S. boulardii is often found in a lyophilized (patented dehydration process) form and is therefore often referred to as Saccharomyces boulardii lyo. Biocodex is the largest manufacturer of S. boulardii lyo, which is marketed under a number of different labels in over 90 countries worldwide: Ultra-Levure, Florastor, Perenterol, Interflora, and more. The S. boulardii lyo manufactured by Biocodex is the strain used in the vast majority of all studies performed on Saccharomyces boulardii. The primary clinically studied strain is designated CNCM I-745.
S. boulardii is sold as a probiotic either as lyophilized or heat-dried powders in capsules, or as one of several strains in a probiotic mixture in capsules or in liquid beverages. Products not stable at room temperature require refrigeration, probably heat-dried. Products stable at room temperature are typically packaged in blister packs and are lyophilized. On the market, there is also the dried yeast powder in sachets, which is considered a comparable dosage form.
The quality of these products from different sources has been found to vary. Choosing a probiotic product from a manufacturer with a regulated quality control program is a sound policy. Unfortunately, many of the products available commercially may lack regulated quality control programs. Studies of other probiotics have found a wide diversity in both quality and contamination in products available on the Internet. Marcobal et al. tested 14 commercial probiotics in the US and found 93% were incorrectly labeled (57% had contaminants and 36% did not list strains on the label).
In 1923, while on an expedition in Southeast Asia, the French microbiologist Henri Boulard made a chance discovery. He observed locals drinking a concoction made from the skins of two tropical fruits, litchis and mangosteens, to relieve stomach problems, including diarrhea. Boulard first isolated the yeast after he observed natives of Southeast Asia chewing on the skin of lychee and mangosteen in an attempt to control the symptoms of cholera.
The discovery of Saccharomyces boulardii dates back to the 1920s, when French microbiologist Henri Boulard isolated the yeast from lychee and mangosteen skins in Indochina (modern-day Vietnam and Cambodia). Recognizing the yeast's therapeutic potential, Boulard isolated and cultured the organism, eventually leading to the development of the commercial probiotic now known as Saccharomyces boulardii. It was not used in ancient herbal medicine or traditional systems like Ayurveda or TCM, since its identification and isolation required microbiological techniques unavailable until the 20th century. However, its practical origin—based on traditional practices involving tropical fruit peels—shows a clear intersection between folk observation and scientific validation.
S. boulardii CNCM I-745 is the first yeast to be demonstrated to have probiotic properties and the first probiotic in human medicine. The yeast has been investigated in more than 100 clinical trials and has been available as a probiotic treatment for diarrhea for over 56 years. Almost 460 million people have been treated with the unique strain Saccharomyces boulardii CNCM I-745 since the 1980s, and it is used in more than 90 countries.
Two main mechanisms were demonstrated: the first is a large capacity of the wall to fix bacteria and toxins which facilitates their elimination during intestinal transit, and the second is the synthesis by this yeast of several active factors.
Castagliuolo et al. found a 54 kDa serine protease produced by S. boulardii that directly degrades C. difficile toxin A and B. This 54 kDa protease identified in the culture supernatant can degrade C. difficile toxins A and B and their receptors.
S. boulardii and S. boulardii-secreted protein(s) inhibit production of proinflammatory cytokines by interfering with the global mediator of inflammation nuclear factor κB (NF-κB), and modulating the activity of the mitogen-activated protein kinases ERK1/2 and p38. S. boulardii activates expression of peroxisome proliferator-activated receptor-gamma (PPAR-γ) that protects from gut inflammation and IBD.
The inflammation associated with C. difficile colitis is due to the activation of pro-inflammatory pathways by toxins A and B: nuclear translocation of NF-κB factor and activation by phosphorylation of MAP kinases that induce cytokine synthesis. The culture supernatant of S. boulardii CNCM I-745 inhibits interleukin 8 (IL-8) synthesis as well as nuclear translocation of NF-κB and inhibits toxin A-induced phosphorylation of ERK1/2 and JNK in epithelial cells.
The effect of S. boulardii CNCM I-745 on IgA is the subject of one of the first studies on the mechanism of action of this yeast. This study showed that S. boulardii CNCM I-745 induces an increase in the concentration of secretory IgA in the intestinal fluid and an increase in the secretory component of the polymeric immunoglobulin receptor in cryptic cells of the intestinal mucosa in young rats 14 days after weaning. S. boulardii induces a specific IgA immune response to toxin A when both are co-administered. The relative increase in specific IgA anti-toxin A production is greater than the observed increase in total IgA levels, consistent with antigen-specific stimulation of the intestinal mucosal immune system.
S. boulardii may interfere with pathogenesis within the intestinal lumen by several mechanisms: either by blocking pathogen toxin receptor sites, or acting as a decoy receptor for the pathogenic toxin, or by direct destruction of the pathogenic toxin. In pre-clinical investigations in animal models or models of intestinal epithelial cells, S. boulardii CNCM I-745 has been demonstrated to counteract harmful bacterial toxins by blocking receptor sites, directly binding the toxin, or producing proteins that destroy them.
S. boulardii also suppresses bacterial overgrowth and host cell adherence, releases a protease that cleaves C. difficile toxin A and its intestinal receptor, and stimulates antibody production against toxin A. Recent results indicate that S. boulardii may interfere with IBD pathogenesis by trapping T cells in mesenteric lymph nodes.
In prior studies, S. boulardii CNCM I-745 was able to maintain the structure of tight junctions in monolayers of infected cells.
S. boulardii produces polyamines (like spermidine and spermine) that enhance intestinal maturation and barrier function.
S. boulardii has been shown to be non-pathogenic, non-systemic (remaining in the gastrointestinal tract), and grows at the unusually high temperature of 37°C. In the period following S. boulardii treatment, concentrations of live cells decreased by three orders of magnitude within 24 hours. However, the authors estimated the half-life value is shorter than 3 hours for live cells. This transient colonization pattern means that continued administration is required to maintain gastrointestinal presence.
Unlike most probiotics, which are bacterial (like Lactobacillus or Bifidobacterium), S. boulardii is a yeast, making it particularly useful in situations where antibiotics are being used, since it is resistant to antibiotic activity.
Of 31 randomized, placebo-controlled treatment arms in 27 trials (encompassing 5,029 study patients), S. boulardii was found to be significantly efficacious and safe in 84% of those treatment arms. S. boulardii probiotics have been tested for clinical efficacy in several types of acute diseases including antibiotic-associated diarrhea, C. difficile infections, Helicobacter pylori disease, acute adult diarrhea, enteral nutrition-related diarrhea, and traveler's diarrhea.
A meta-analysis found a significant therapeutic efficacy for S. boulardii in the prevention of antibiotic-associated diarrhea (AAD) (RR = 0.47, 95% CI: 0.35–0.63, P < 0.001). In adults, S. boulardii can be strongly recommended for the prevention of AAD and traveler's diarrhea.
Of the 10 controlled trials in adults using S. boulardii for the prevention of AAD, 8 (80%) showed significant efficacy for the prevention of AAD.
Importantly, not all trials show uniform benefit. One randomized, double-masked, placebo-controlled trial found no evidence for an effect of S. boulardii in preventing AAD or C. difficile-associated diarrhea (CDAD) in a population of hospitalized patients without particular risk factors apart from systemic antibiotic treatment. This underscores that the benefit may be most pronounced in higher-risk populations or specific clinical contexts.
Evidence strength: Strong; supported by multiple randomized controlled trials (RCTs) and several meta-analyses. The overall reduction in AAD risk is substantial, though some individual trials are negative.
A systematic review found that Saccharomyces boulardii was well tolerated and significantly reduced recurrent antibiotic-associated diarrhoea caused by Clostridium difficile infection, particularly with concurrent high-dose vancomycin. Its effect on primary prevention was not significant.
S. boulardii shows promise for the prevention of C. difficile disease recurrences, but more supporting evidence is recommended for this indication.
In a randomized controlled trial evaluating S. boulardii as adjunct therapy with vancomycin in treating CDI, clinical cure rates were similar between groups (98.4% vs. 98.3%), but the combination group had a significantly higher global cure rate.
Evidence strength: Moderate for reducing recurrence; weaker for primary prevention. Results are mixed and dependent on the specific clinical context, particularly whether high-dose vancomycin is co-administered. Additional large, well-controlled trials are needed.
A meta-analysis included 10 articles with a total of 1,282 children having acute gastroenteritis. The use of Saccharomyces boulardii in children with acute gastroenteritis could effectively shorten diarrhea duration (MD = 19.70 hours, 95% CI: −24.87, −14.52) and reduce the length of hospital stay (MD = −0.91 days, 95% CI: −1.28, −0.54). Compared with the control group, the relative risk of continued diarrhea was significantly lower in the treatment group after 1 day and 3 days of treatment. Treatment with Saccharomyces boulardii also reduced the average number of diarrheal episodes after 3 days of treatment by about 1.03. There were no adverse drug reactions in either group.
A randomized, double-blind, placebo-controlled multicenter trial assessed the efficacy and safety of Saccharomyces cerevisiae variant boulardii CNCM I-3799 in the management of acute diarrhea in children. A total of 100 infants and children 3–36 months of age with acute diarrhea received care according to WHO guidelines and were randomly allocated to the probiotic group (S. boulardii CNCM I-3799 at a daily dose of 5 billion CFU twice daily) or to the placebo group. Children were treated for 5 days. The primary endpoint was the duration of diarrhea.
S. boulardii CNCM I-745 was found to significantly reduce the duration of pediatric acute gastroenteritis, significantly improved diarrheal symptoms, and had a higher cure rate compared to controls in patients in China in a dedicated meta-analysis.
Evidence strength: Good to strong; multiple RCTs and meta-analyses across several populations support efficacy for reduction in diarrhea duration and hospitalization in pediatric acute gastroenteritis.
In adults, S. boulardii can be strongly recommended for the prevention of traveler's diarrhea. Saccharomyces boulardii was shown to prevent traveler's diarrhea but further studies are needed for firm conclusions. Lactobacillus rhamnosus and S. boulardii are recommended in the treatment of acute infectious diarrhea.
Evidence strength: Moderate to good, based on RCTs, though the evidence base for prevention is somewhat smaller than for AAD. The McFarland (2010) systematic review and meta-analysis included this as one of two indications for which S. boulardii can be "strongly recommended" in adults.
Randomized trials also support the use of this yeast probiotic for prevention of enteral nutrition-related diarrhea and reduction of Helicobacter pylori treatment-related symptoms.
Three hundred and sixty H. pylori-infected patients were recruited in a multicenter, randomized controlled trial. Patients undergoing H. pylori eradication treatment were randomized 1:1 to standard quadruple therapy (Group A) and quadruple therapy plus S. boulardii sachets (Group B) for 14 days. S. boulardii and quadruple therapy markedly improved overall pre-eradication alimentary symptoms recovery (hazard ratio: 2.507, 95% CI: 1.449–4.338). Saccharomyces boulardii ameliorated H. pylori eradication-induced antibiotic-associated side effects, especially reducing the incidence of severe diarrhea and the duration of diarrhea. However, there was no significant effect of S. boulardii on the rate of H. pylori eradication.
Addition of probiotics to current Helicobacter pylori eradication regimens can further increase the eradication rate, though evidence specifically for S. boulardii increasing eradication rates remains mixed across individual trials.
Evidence strength: Moderate. S. boulardii appears to consistently reduce GI side effects from eradication therapy, but its impact on the eradication rate itself is inconsistent across trials. Multiple RCTs support the role as an adjunct for tolerability.
Clinical as well as experimental evidence with mouse models of inflammation suggest that this probiotic yeast may have therapeutic potential for IBD patients.
Three of the clinical trials showed a positive effect of S. boulardii in IBD patients (two Crohn's disease, one ulcerative colitis), while there was one trial that did not prove any effect (Crohn's disease). Included animal trials and cell assays describe different anti-inflammatory mechanisms of S. boulardii supporting a possible effect when treating IBD patients. The number of studies of S. boulardii as treatment for IBD is limited. Furthermore, the existing trials have small populations and short duration. There is not enough evidence to prove the effect of S. boulardii in IBD. Saccharomyces boulardii is, however, a plausible treatment option in the future, but more placebo-controlled clinical studies on both patients with ulcerative colitis and Crohn's disease are needed.
In a small pilot study of 31 patients with Crohn's disease in remission all patients continued their maintenance medications and were randomized to either S. boulardii for 3 months or placebo. Those treated with S. boulardii were found to have a significant reduction in colonic permeability compared with those given placebo, thus reducing the risk of bacterial translocation in these patients.
Evidence strength: Weak to preliminary. Anti-inflammatory mechanisms are well-characterized in preclinical models, but clinical trial evidence in humans is limited by small sample sizes, short follow-up, and inconsistent results.
S. boulardii shows promise for the treatment of irritable bowel syndrome, Crohn's disease, giardiasis, and human immunodeficiency virus-related diarrhea, but more supporting evidence is recommended for these indications.
S. boulardii has been tested for clinical efficacy in several types of chronic diseases including Crohn's disease, irritable bowel syndrome, giardiasis and human immunodeficiency virus (HIV)-related diarrhea.
Evidence strength: Preliminary to insufficient for most of these indications. There is a plausible mechanistic rationale and preliminary clinical signals, but large, well-designed RCTs are lacking.
Little is known about the efficacy of S. boulardii against protozoal infections but this probiotic seems to have a beneficial effect in amebiasis, giardiasis, and infection with Blastocystis hominis. In adults, co-administration of lyophilized S. boulardii with conventional treatment in acute amebic colitis significantly decreased the duration of symptoms and cyst carriage after 4 weeks. A prospective RCT in patients with amebic colitis showed that addition of S. boulardii to metronidazole enhanced clearance of cysts and decreased the mean duration of diarrhea, fever, and abdominal pain.
Evidence strength: Preliminary. Evidence is based on small RCTs. Results are encouraging but insufficient to establish definitive clinical recommendations.
In one clinical study, S. boulardii dosing consisted of two 250 mg capsules by mouth twice daily. Each 250 mg capsule contained 5 billion colony-forming units (CFUs), for a total daily administration of 20 billion CFUs.
The typical adult dosage of S. boulardii in clinical studies ranges from 250 to 500 mg once or twice daily, often administered for a duration of 7–14 days depending on the indication.
In a multicenter pediatric RCT, children 3–36 months of age with acute diarrhea received S. boulardii CNCM I-3799 at a daily dose of 5 billion CFU twice daily (total 10 billion CFU/day).
The reference specification of 5 × 109 cells per gram of lyophilisate is cited in the EMA assessment report for S. boulardii.
Unlike many bacterial probiotics, there are few drug or antibiotic interactions with S. boulardii. However, if patients are on antifungal medications, a staggered dose regimen (at least 4 hours apart) is suggested.
Safety and adverse event data collected during clinical trials have documented a remarkable safety profile of S. boulardii in adults. Safety data exist for a total of 2,963 adult patients across multiple disease indications. The only adverse reactions associated with S. boulardii were thirst (in 5 patients) and constipation (in 8 patients) in a trial of patients with C. difficile infections. No case of S. boulardii fungemia was reported in these diverse patient populations enrolled in clinical trials.
In the pediatric meta-analysis, there were no adverse drug reactions in either the treatment or control groups.
While Saccharomyces boulardii is a widely used probiotic for managing antibiotic-associated diarrhea and other gastrointestinal disorders and is considered safe in immunocompetent individuals, its use in critically ill patients has been increasingly associated with invasive fungal infections, particularly Saccharomyces cerevisiae fungemia.
A few case reports have documented S. boulardii-associated fungemia in intensive care unit (ICU) patients, often leading to systemic infections, septic shock, and in some instances, mortality. Risk factors include the presence of central venous catheters (CVCs), impaired mucosal barriers, broad-spectrum antibiotic use, gastrointestinal pathology, and immunosuppression.
One published case report describes a 79-year-old woman with rheumatoid arthritis who, after a bowel resection, developed S. boulardii fungemia. Her postoperative course was complicated by nutritional problems, anaemia, and several nosocomial infections including recurrent C. difficile-associated diarrhea. The patient developed S. boulardii fungemia as an adverse effect of treatment with the probiotic.
Even though fungemia with S. boulardii is infrequent, it may be prudent to closely follow up adult inpatients who are severely ill or in intensive care units and have a central catheter for episodes of unexplained fever. Some studies have recommended not to give S. boulardii to immunosuppressed patients or those with central catheters to reduce this risk.
S. cerevisiae var. boulardii probiotics are not recommended for patients who have indwelling catheters, are immunocompromised, or are critically ill.
Unlike many bacterial probiotics, there are few drug or antibiotic interactions with S. boulardii. However, if patients are on antifungal medications, a staggered dose regimen (at least 4 hours apart) is suggested. This is because antifungal agents active against Saccharomyces species would be expected to kill or reduce the viability of the administered probiotic yeast if taken concurrently.
The quality of commercial products varies. Choosing a probiotic product from a manufacturer with a regulated quality control program is important. Unfortunately, many of the products available commercially may lack regulated quality control programs. Studies of other probiotics have found a wide diversity in both quality and contamination in products available on the Internet.
Condiciones de salud que Saccharomyces boulardii puede ayudar a apoyar.
Saccharomyces boulardii is a well-studied probiotic yeast with evidence for reducing GI symptoms including abdominal discomfort in IBS and antibiotic-associated diarrhea. It is listed among the probiotics with clinical evidence for IBS-related abdominal symptom relief in systematic reviews and authoritative clinical references.
Saccharomyces boulardii is a non-pathogenic probiotic yeast with the strongest clinical evidence among probiotics for inhibiting Candida colonization. Clinical studies confirm significant reductions in vaginal yeast colonization, and it is the only commercially available probiotic yeast with evidence for Candida inhibition. Multiple mechanisms including Candida virulence inhibition are documented.
Saccharomyces boulardii is a non-pathogenic probiotic yeast with documented in vitro inhibition of Candida albicans growth and competitive exclusion activity. It modulates gut microbiota, reduces dysbiosis, and has been studied in over 90 RCTs for various gastrointestinal conditions, supporting its use in Candida cleanse protocols to re-establish microbial balance and prevent Candida recolonization.
Saccharomyces boulardii KK1 reduced CD71 expression, cytokine production, and CeD-like histological changes in a mouse model when fed gluten digested with this yeast. S. boulardii CNCM I-745 reduced gluten immunopathology in immunized NOD/DQ8 mice via AhR pathway activation and synergizes with duodenal microbiota from CeD patients to increase tryptophan and AhR signaling, with researchers calling for clinical trials.
Saccharomyces boulardii is one of the two most recommended probiotic interventions in pediatric gastroenterology guidelines, alongside Lactobacillus rhamnosus GG. A 2022 systematic review and meta-analysis of 10 RCTs in 1,282 children under 5 confirmed it shortens diarrhea duration and reduces hospital stay in acute gastroenteritis. It is endorsed for pediatric use by multiple international guidelines.
Multiple RCTs and a systematic meta-analysis demonstrate that S. boulardii reduces diarrhea duration and hospitalisation in children with acute gastroenteritis. It stimulates secretory IgA production and decreases C-reactive protein, reflecting direct immunomodulatory activity in pediatric populations. Evidence is strongest for acute gastroenteritis and prevention of antibiotic-associated diarrhea.
S. boulardii inhibits key inflammatory signaling pathways including NF-κB and MAP kinases (ERK1/2, p38), reducing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8 while upregulating anti-inflammatory mediators. Clinical evidence from IBD and cirrhosis RCTs confirms reductions in inflammatory markers. These effects underpin its utility across multiple chronic inflammatory gastrointestinal conditions.
Saccharomyces boulardii has been evaluated in a pilot trial for ulcerative colitis and in animal models of DSS-induced colitis, showing modulation of NF-κB and Nrf2 signaling. It has well-established evidence for C. difficile-associated colitis and antibiotic-associated colitis. Anti-inflammatory mechanisms in UC have been described.
S. boulardii supplementation significantly reduces constipation as a side effect of H. pylori eradication therapy in adults, supported by multiple meta-analyses. A multicenter RCT in children with functional constipation also investigated S. boulardii monotherapy. Preclinical data suggest mechanisms involving serotonin pathway modulation and increased short-chain fatty acid production.
S. boulardii has been evaluated in multiple clinical trials for Crohn's disease (CD), showing mixed results. An early small RCT found a marked reduction in relapse when combined with mesalamine, but a larger placebo-controlled trial (FLORABEST, n=165) failed to show benefit for relapse prevention. It improves intestinal permeability in CD patients in remission, and it is supported by mechanistic anti-inflammatory evidence.
Saccharomyces boulardii is among the most evidence-supported probiotics for diarrhea. Cochrane reviews and multiple meta-analyses confirm it reduces duration and incidence of antibiotic-associated diarrhea, traveler's diarrhea, and acute infectious diarrhea in children and adults. One network meta-analysis (84 RCTs, 13,443 children) found it reduced diarrhea duration by approximately 1.25 days vs. placebo (moderate certainty).
S. boulardii CNCM I-745 synthesizes polyamines that upregulate intestinal brush-border digestive enzymes including lactase, sucrase-isomaltase, and trehalase, and also directly secretes certain enzymes. These trophic effects have been documented in a dedicated peer-reviewed review of non-clinical and clinical studies.
Saccharomyces boulardii is specifically listed by Atlantic Health's evidence-based complementary medicine resource for diverticulitis as a probiotic to help maintain intestinal health. It is a non-pathogenic yeast probiotic widely studied for gastrointestinal inflammation and dysbiosis, both central to diverticular disease pathophysiology.
Saccharomyces boulardii is a non-pathogenic probiotic yeast with established evidence for improving gut barrier function and GI microbiota health, and is used clinically in conditions of intestinal inflammation and dysbiosis that underlie food sensitivity. The European Society of Paediatric Gastroenterology recommends it for GI conditions and it has documented effects on reducing intestinal permeability.
Saccharomyces boulardii is the most extensively studied single probiotic strain for H. pylori eradication as adjunct therapy. A high-quality systematic review (2025, 19 RCTs, 5,036 cases) confirmed significant improvement in H. pylori eradication rates with S. boulardii supplementation. It also reduces antibiotic-associated side effects during H. pylori gastritis treatment.
Saccharomyces boulardii is the most studied probiotic yeast, validated in over 90 randomized clinical trials for gut microbiome modulation, prevention of antibiotic-associated diarrhea, and treatment of C. difficile-associated disease. ESPGHAN guidelines recommend it for acute infectious diarrhea, and it significantly modulates gut microbial composition.
Saccharomyces boulardii is a non-pathogenic yeast classified as a probiotic and is identified in peer-reviewed literature as a main probiotic member relevant to gut-brain axis modulation. It supports gut barrier function, reduces gut-derived neuroinflammation, and is among the most studied yeast probiotics for GI and systemic health with neurological implications.
Saccharomyces boulardii is among probiotics specifically named in a 2017 systematic review as effective for ameliorating IBS symptoms. It is the primary probiotic recommendation for IBS-D in some clinical guidelines. A 2025 strain-specific meta-analysis found conflicting results for CNCM I-745 specifically, but multiple individual trials support its use, particularly for diarrhea-predominant IBS.
Saccharomyces boulardii is a probiotic yeast with pilot study evidence for efficacy in UC and Crohn's disease. It has demonstrated clinical benefit in UC as add-on therapy to mesalazine and reduced stool frequency in CD. Mechanistically, it controls intestinal inflammation via dendritic cell modulation and NF-κB inhibition.
S. boulardii CNCM I-745 enhances intestinal lactase activity through polyamine-mediated upregulation of brush-border enzymes, providing a documented mechanistic basis for symptom relief in lactase-deficient individuals. This trophic effect on lactase is described in peer-reviewed mechanistic literature, though large dedicated clinical trials in lactose intolerant populations are lacking.
Saccharomyces boulardii is a non-pathogenic probiotic yeast with substantial evidence for intestinal barrier protection. A comprehensive PMC review (PMC6375115) documents that S. boulardii CNCM I-745 restores epithelial barrier defects in IBD, infectious diarrhea, and metabolic syndrome through multiple tight junction-preserving mechanisms. The Mayo Clinic conducted a placebo-controlled parallel-group clinical trial specifically assessing its ability to counteract NSAID-induced intestinal hyperpermeability.
Saccharomyces boulardii is a clinically established probiotic yeast with documented mycotoxin-binding effects mediated by cell wall beta-glucans, mannans, and chitin, achieving up to 96.9% removal of aflatoxin M1 in reconstituted milk. It also reverses mycotoxin-induced cellular injury by modulating the p38 MAPK signaling pathway. Both adsorption and active biotransformation mechanisms contribute to its mycotoxin detoxification role, making it uniquely suited for gut-level mycotoxin support.
Meta-analyses of S. boulardii as adjuvant to H. pylori eradication therapy show a statistically significant reduction in nausea (RR≈0.50), but not vomiting specifically. In pediatric gastroenteritis, S. boulardii reduces vomiting duration as part of its broader anti-gastroenteritis effect. Evidence is strongest for nausea as a side-effect of antibiotic regimens.
A yeast probiotic with robust clinical evidence for restoring gut health during and after infectious illness and antibiotic therapy. Multiple RCTs and Cochrane reviews support its efficacy in reducing diarrhea duration and restoring microbiome balance—key components of post-illness digestive and immune recovery.
Saccharomyces boulardii is a probiotic yeast with multiple RCTs demonstrating efficacy for SIBO. A 2024 randomized placebo-controlled study in patients with decompensated cirrhosis found SIBO absent in 80% of the probiotic group vs. 23.1% of placebo (p=0.002) after 3 months. A 2017 meta-analysis (18 studies, J Clin Gastroenterol) found probiotics including S. boulardii significantly reduced bacterial overgrowth and hydrogen breath test concentrations.
S. boulardii acts as an adjuvant to standard H. pylori eradication therapy—the primary driver of peptic ulcer disease—improving eradication rates and reducing therapy-associated side effects in multiple meta-analyses. It does not treat ulcers directly but demonstrably improves the success of the antibiotic regimens that heal them.
Saccharomyces boulardii is a beneficial yeast probiotic with documented effects on gut microbiome composition. By reducing intestinal uropathogen populations (particularly E. coli) via the gut-urinary axis, it indirectly supports urinary flora health. It is included in probiotic formulations for microbiome restoration and is used clinically to restore gut flora following antibiotic treatment — antibiotic disruption of gut flora is a key driver of increased UTI susceptibility.
Sistemas corporales que Saccharomyces boulardii puede ayudar a apoyar.
Volver